Pik3ca-related Overgrowth Spectrum

• CLINICAL_TRIALS research · 2026-04-24
  Clinical Trial Update: Study of Proteus Syndrome and Related Congenital Disorders

  Clinical trial update noting that the study examining Proteus syndrome and PIK3CA-related overgrowth spectrum is currently recruiting.

• CLINICAL_TRIALS research · 2026-04-14
  Clinical Trial Update: Managed Access Programs for BYL719, Alpelisib

  Novartis' alpelisib (BYL719) is available through managed access programs for PIK3CA-Related Overgrowth Spectrum and breast cancer.

• CLINICAL_TRIALS research · 2026-04-06
  Clinical Trial Update: EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS) [Phase 2]

  A Phase II single-arm trial (EPIK-P4) is evaluating the efficacy, safety, and pharmacokinetics of alpelisib in pediatric and adult patients …

• CLINICAL_TRIALS trial_result · 2026-04-02
  Clinical Trial Update: Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1) [Phase 2]

  This clinical trial update describes a Phase 2 long-term safety and efficacy study of alpelisib in patients with PIK3CA-related overgrowth s…

• CLINICAL_TRIALS trial_result · 2026-02-23
  Clinical Trial Update: National Evaluation of Patients With PIK3CA-Related Overgrowth Spectrum (PROS)

  The PROS clinical trial (NCT05563831) has completed, providing an update on patients with PIK3CA-related overgrowth spectrum and related con…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS research · 2026-01-08
  Clinical Trial Update: A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation [Phase 2]

  Phase 2 clinical trial update for RLY-2608, a mutant-selective PI3Kα inhibitor, in adults and children with PIK3CA-related overgrowth spectr…

• CLINICAL_TRIALS trial_result · 2025-11-21
  Clinical Trial Update: Sirolimus Effect on Hypertrophic Syndromes Related Gene PIK3CA [Phase 2]

  Phase 2 clinical trial evaluating the effect of sirolimus on hypertrophic syndromes related to PIK3CA has completed.

• CLINICAL_TRIALS trial_result · 2025-10-29
  Clinical Trial Update: A Study of the Epidemiology and Hospital Management of Patients With PROS in France

  This completed French study investigates the epidemiology and hospital management of patients with PIK3CA-related overgrowth spectrum (PROS)…

• CLINICAL_TRIALS research · 2025-09-24
  Clinical Trial Update: Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Patients With PIK3CA-related Overgrowth Spectrum (PROS) and PIK3CA-related Vascular Malformations (PRVM) [Phase 1, Phase 2]

  A Phase 1/2 clinical trial is evaluating CYH33 for PIK3CA-related Overgrowth Spectrum (PROS) and PIK3CA-related Vascular Malformations (PRVM…

• CLINICAL_TRIALS research · 2025-06-24
  Clinical Trial Update: Health-related Quality of Life, Symptom Severity, and Pain Among Patients With PIK3CA-related Overgrowth Spectrum: A Mixed-methods Observational Study

  This completed observational study evaluated health-related quality of life, symptom severity, and pain in patients with PIK3CA-related Over…

• CLINICAL_TRIALS trial_result · 2025-02-10
  Clinical Trial Update: Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum [Phase 2]

  This Phase 2 study reports results on alpelisib (BYL719) for PIK3CA-related overgrowth spectrum (PROS) in pediatric and adult patients, asse…

• CLINICAL_TRIALS research · 2025-02-07
  Clinical Trial Update: A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006) [Phase 2]

  This is a Phase 2 clinical trial update on the safety and tolerability of miransertib (MK-7075) in participants with PIK3CA-related overgrow…

• CLINICAL_TRIALS trial_result · 2023-03-31
  Clinical Trial Update: Study of Miransertib (MK-7075) in Participants With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC) (MK-7075-002) [Phase 1, Phase 2]

  Clinical trial update for miransertib in PROS and Proteus Syndrome (MOSAIC) shows the study was terminated; results were posted in 2023.

• CLINICAL_TRIALS trial_result · 2023-02-09
  Clinical Trial Update: Retrospective Chart Review Study of Patients With PIK3CA-Related Overgrowth Spectrum Who Have Received Alpelisib

  A retrospective chart review studying patients with PIK3CA-Related Overgrowth Spectrum who received alpelisib; completed with results posted…

• CLINICAL_TRIALS trial_result · 2020-01-27
  Clinical Trial Update: Study of Sirolimus Therapy for Segmental Overgrowth Caused by Somatic PI3K Activation [Phase 2]

  Phase 2 trial evaluating sirolimus for segmental overgrowth due to somatic PI3K activation (PROS) has completed with results posted.